Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer

Trial Profile

Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Crizotinib (Primary) ; Itraconazole; Rifampicin
  • Indications Anaplastic large cell lymphoma; Cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms PROFILE-1001
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Aug 2017 Planned End Date changed from 1 Nov 2019 to 11 Nov 2019.
    • 17 Aug 2017 Planned primary completion date changed from 1 Nov 2019 to 11 Nov 2019.
    • 15 Mar 2017 Planned number of patients changed from 580 to 600.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top